Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05268003 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

A Phase 2 study of Leukemia and Acute Lymphoblastic Leukemia, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
26
Enrollment target
1
Study location

NCT05268003: Active Phase 2 study of Leukemia and Acute Lymphoblastic Leukemia, sponsored by M.D. Anderson Cancer Center.

NCT05268003 is a Phase 2 study of Leukemia and Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05268003, a Phase 2 study of Leukemia and Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia

Conditions Studied

Leukemia Acute Lymphoblastic Leukemia

Interventions

  • DRUG Venetoclax
  • DRUG Ponatinib
  • DRUG Mini-hyper CVD

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2022-06-07
Est. Completion 2026-10-05
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT05268003 still lists

NCT05268003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT05268003 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05268003 about?

NCT05268003 is a clinical study titled "A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia". The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia

What is the current status of trial NCT05268003?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2022-06-07. Estimated completion is 2026-10-05.

What conditions does trial NCT05268003 study?

This clinical trial studies the following conditions: Leukemia, Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT05268003?

The interventions under investigation include: Venetoclax (DRUG), Ponatinib (DRUG), Mini-hyper CVD (DRUG).

Who is sponsoring clinical trial NCT05268003?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05268003 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05268003's enrollment target sits among peer trials

26 172nd of 233 higher than 62 of 233 other Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05268003, the US trial registry maintained by the National Library of Medicine. NCT05268003 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.